Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness

Only a subset of cancer patients responds to checkpoint blockade inhibition in the clinic. Strategies to overcome resistance are promising areas of investigation. Targeting glucocorticoid-induced tumor necrosis factor receptor–related protein (GITR) has shown efficacy in preclinical models, but GITR...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirschhorn, Daniel, Betof Warner, Allison, Maniyar, Rachana, Chow, Andrew, Mangarin, Levi M.B., Cohen, Adam D., Hamadene, Linda, Rizzuto, Gabrielle A., Budhu, Sadna, Suek, Nathan, Liu, Cailian, Houghton, Alan N., Merghoub, Taha, Wolchok, Jedd D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564916/
https://www.ncbi.nlm.nih.gov/pubmed/34676831
http://dx.doi.org/10.1172/jci.insight.151035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564916/
https://www.ncbi.nlm.nih.gov/pubmed/34676831
http://dx.doi.org/10.1172/jci.insight.151035

Ejemplares similares